MAST: Metformin for Reducing Progression in Patients on Management for Low-Risk Prostate Cancer

Anthony M. Joshua, MBBS, PhD, FRACP, of St. Vincent’s Hospital Sydney, and Christopher Wallis, MD, PhD, FRCSC, of University of Toronto, contextualize the Metformin Active Surveillance Trial (MAST).

This study was a randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer.